Target intelligence / Profile preview

Amyloid-beta peptide (Abeta) (Abeta)

Target
Abeta
Molecular classification
Peptide, Protein aggregate
01

Overview

Amyloid-beta (Aβ) is a peptide of 36–43 amino acids that is the primary component of the amyloid plaques found in the brains of patients with Alzheimer's disease (UniProt P05067). It is produced through the sequential proteolytic cleavage of the Amyloid-beta precursor protein (APP) by beta-secretase (BACE1) and gamma-secretase (Selkoe & Hardy, 2016). In pathological states, Aβ monomers aggregate into soluble oligomers, protofibrils, and insoluble fibrils, which are thought to be the primary drivers of neurotoxicity (Hardy & Higgins, 1992). These aggregates disrupt synaptic transmission, induce oxidative stress, and trigger a neuroinflammatory response involving microglial activation (Jack et al., 2018). The Amyloid Hypothesis posits that the accumulation of Aβ is the fundamental cause of Alzheimer's disease, initiating a cascade that includes tau protein hyperphosphorylation and neuronal death (Selkoe & Hardy, 2016). Therapeutic interventions have focused on reducing Aβ levels through secretase inhibition or enhancing clearance via passive immunotherapy with monoclonal antibodies (FDA, 2023). Drugs such as Lecanemab and Aducanumab specifically target aggregated forms of Aβ to reduce plaque burden in the brain (FDA, 2023). Clinical monitoring of these therapies often involves assessing Amyloid-related imaging abnormalities (ARIA), which represent a significant safety concern (Sperling et al., 2011). Biomarkers such as the CSF Aβ42/Aβ40 ratio and Amyloid PET imaging are essential for patient selection and monitoring treatment efficacy (Jack et al., 2018).

Other names
Beta-amyloidA-betaAmyloid-betaAbeta peptide
02

Mechanism of action

Monoclonal antibodies bind to specific species of amyloid-beta (such as monomers, oligomers, protofibrils, or plaques) to neutralize their toxicity and promote clearance from the brain via microglial-mediated phagocytosis. Other mechanisms include the inhibition of beta-secretase (BACE1) or gamma-secretase to reduce the production of the peptide from its precursor protein.

03

Biological functions

Synaptic plasticityNeurotoxicityAntimicrobial activityCell signaling
04

Disease associations

Alzheimer's diseaseCerebral amyloid angiopathyDown syndrome
05

Safety considerations

Amyloid-related imaging abnormalities (ARIA-E and ARIA-H)Vasogenic edemaCerebral microhemorrhageInfusion-related reactions
06

Interacting drugs

Aducanumab

6 more in the full profile.

07

Biomarkers

CSF Aβ42/Aβ40 ratioAmyloid PET imaging (e.g., Florbetapir)Plasma Aβ42/Aβ40Plasma p-tau181

Beyond the preview

Go deeper on Amyloid-beta peptide (Abeta) (Abeta).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amyloid-beta peptide (Abeta) (Abeta).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call